author-photo

Jeffrey Schlom

National Institutes of Health
Columbia University

1017

Papers

41960

Citations

Citation Trend

Filter By

Papers (1017) Sort By

JournalConferenceOthers

First-in-human phase I/II trial of PRGN-2009 vaccine as monotherapy or with bintrafusp alfa in patients with recurrent/metastatic (R/M) human papillomavirus (HPV)-associated cancers (HPVC) and as neoadjuvant/induction therapy in locoregionally advanced (LA) HPV oropharyngeal (OP) and sinonasal (SN) squamous cell cancer (SCC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
582 Immune correlates from QuEST1 in men with castration-resistant prostate cancer

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Vaccine Increases the Diversity and Activation of Intratumoral T Cells in the Context of Combination Immunotherapy.

2021 Cancers
Show All
- Source
- Cite
- Save
Citations (3)
540 Baseline mTOR transcriptional signatures in CD8 T cells are associated with immune-related adverse events but not anti-tumor responses in patients receiving immune checkpoint inhibitors

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
A phase I/II study of bintrafusp alfa and NHS-IL12 in combination with docetaxel in adults with metastatic castration sensitive (mCSPC) and castration-resistant prostate cancer (mCRPC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma.

2021 Oncologist
Show All
- Source
- Cite
- Save
Citations (4)
Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis.

2021
Show All
- Source
- Cite
- Save
Citations (0)
6 Immune correlates of clinical benefit in patients with HPV-associated malignancies treated with bintrafusp alfa

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC).

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (5)
727 Resistance to enzalutamide and abiraterone drives tumor phenotypic plasticity and resistance to immune-mediated cytotoxicity

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)

© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.

沪ICP备18028330号